Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INJECTAPAP vs OCALIVA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Ocaliva (obeticholic acid) is a farnesoid X receptor (FXR) agonist. FXR is a nuclear receptor that regulates bile acid synthesis, transport, and homeostasis. Activation of FXR reduces the production of bile acids by suppressing cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis, and increases the expression of FXR target genes involved in bile acid transport and detoxification.
Management of mild to moderate pain,Reduction of fever
Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
5 mg orally once daily, increase to 10 mg once daily if adequate response after 3 months.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
The terminal elimination half-life of obeticholic acid is approximately 24 hours for the parent drug and 3.5 to 5.8 days for its active conjugates (glyco- and tauro-obeticholic acid). This long half-life supports once-daily dosing but indicates that steady-state is reached after about 2 weeks.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Obeticholic acid is metabolized in the liver and intestine via conjugation with glycine or taurine, and subsequently undergoes extensive enterohepatic recirculation. It is not significantly metabolized by CYP450 enzymes. The conjugated metabolites are eliminated in feces.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Following oral administration, approximately 87% of the dose is excreted in feces (primarily as unchanged drug and metabolites) and less than 3% is excreted renally. Biliary excretion is the major route for the parent drug and its conjugates.
10-25% bound to albumin at therapeutic concentrations.
Obeticholic acid is approximately 99% bound to plasma proteins, primarily albumin.
0.8-1.0 L/kg; suggests distribution into total body water.
The volume of distribution is approximately 6.5 L/kg, indicating extensive extravascular distribution, consistent with its lipophilic nature and high tissue binding, particularly to liver and intestinal tissues.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
Absolute bioavailability of oral obeticholic acid is approximately 50%, with a range of 30-70% due to first-pass hepatic metabolism and conjugation.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m2).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Child-Pugh class A: No adjustment. Child-Pugh class B: Initial dose 5 mg once daily, increase to 10 mg if tolerated. Child-Pugh class C: Contraindicated.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
No specific dose adjustment; use caution due to potential for increased exposure and hepatic impairment.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
WARNING: HEPATIC DECOMPENSATION AND LIVER FAILURE IN INCORRECTLY DOSED PBC PATIENTS WITH CHILD-PUGH CLASS B OR DECOMPENSATED CIRRHOSIS. Patients with Child-Pugh class B or decompensated cirrhosis (Child-Pugh class C) are at increased risk of hepatic decompensation and liver failure when incorrectly dosed. Ocaliva is contraindicated in patients with decompensated cirrhosis (Child-Pugh class C). In patients with Child-Pugh class B, the starting dose is 5 mg once weekly, with dose adjustment based on response and tolerability.
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Hepatic decompensation and liver failure in patients with Child-Pugh class B or decompensated cirrhosis,Risk of hepatic decompensation in patients with moderate to severe hepatic impairment,Severe pruritus: dose reduction, antihistamines, or bile acid resins may be considered,Reduction in HDL-C levels; monitor lipid levels periodically,Monitor liver function tests (e.g., bilirubin, INR) and signs of hepatic decompensation
Hypersensitivity to acetaminophen or any component of the formulation
Complete biliary obstruction,Decompensated cirrhosis (Child-Pugh class C),Known hypersensitivity to obeticholic acid or any component of the formulation
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
No specific food restrictions; however, consistent administration with or without food is recommended. Avoid grapefruit juice as it may increase drug exposure. Limit alcohol consumption to reduce liver stress.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
There are no adequate and well-controlled studies of Ocaliva in pregnant women. In animal reproduction studies, oral administration of obeticholic acid to pregnant rats and rabbits during organogenesis at doses less than the maximum recommended human dose (MRHD) resulted in embryofetal mortality and malformations. Based on animal data, Ocaliva may cause fetal harm when administered to a pregnant woman. Avoid use during pregnancy, especially in the first trimester, unless the potential benefit to the mother outweighs the potential risk to the fetus.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
It is not known whether obeticholic acid is excreted in human milk. In animal studies, obeticholic acid and/or its metabolites were detected in milk of lactating rats. The M/P ratio is not available. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Ocaliva, women should not breastfeed during treatment and for 3 weeks after the last dose.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
No specific dose adjustments for pregnancy are provided in the labeling. Ocaliva is contraindicated in patients with complete biliary obstruction, and use during pregnancy should be avoided. If use is essential, no data exist to guide dose modifications; pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) may necessitate empiric dose adjustment, but no formal studies have been conducted.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
OCALIVA (obeticholic acid) is a farnesoid X receptor agonist for primary biliary cholangitis (PBC). Monitor liver function tests closely; dose adjustments needed in moderate to severe hepatic impairment (Child-Pugh B or C). Titrate from 5 mg to 10 mg based on tolerability after 3 months. Contraindicated in patients with complete biliary obstruction. Pruritus is common; consider antihistamines or bile acid binders. Check INR if on warfarin due to potential interaction.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
Take with or without food, but be consistent with meals to maintain stable drug levels.,Do not stop or change dose without consulting your healthcare provider.,Report severe itching, jaundice, or dark urine immediately.,Avoid alcohol and medications that can harm the liver.,Inform all healthcare providers you are taking this medication.,Attend regular blood tests to monitor liver function and treatment response.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INJECTAPAP vs OCALIVA, answered by our medical review team.
INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. OCALIVA is a Farnesoid X receptor agonist that works by Ocaliva (obeticholic acid) is a farnesoid X receptor (FXR) agonist. FXR is a nuclear receptor that regulates bile acid synthesis, transport, and homeostasis. Activation of FXR reduces the production of bile acids by suppressing cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis, and increases the expression of FXR target genes involved in bile acid transport and detoxification.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INJECTAPAP and OCALIVA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. The standard adult dose of OCALIVA is: 5 mg orally once daily, increase to 10 mg once daily if adequate response after 3 months.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INJECTAPAP and OCALIVA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. OCALIVA is classified as Category C. There are no adequate and well-controlled studies of Ocaliva in pregnant women. In animal reproduction studies, oral administration of obeticholic acid to pregnant rats and rabbits. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.